Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week open-label ABBV-951 continuous subcutaneous infusion in Parkinson's disease
jRCT2080224809Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2019
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of foscarbidopa in Parkinson's disease (PD), sponsored by AbbVie Inc. Primary endpoint: Safety and tolerability of ABBV-951 continuous subcutaneous infusion over 52 weeks. Started Jul 2019; status: completed.
02
Drugs
foscarbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on jRCT2080224809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224809.